tldrdailynews.com logo
Tag

Astrazeneca

All articles tagged with #astrazeneca

AstraZeneca stock slides after FDA advisory panel rejects camizestrant
business25 days ago

AstraZeneca stock slides after FDA advisory panel rejects camizestrant

An FDA advisory panel voted 6-3 against approving AstraZeneca's oral breast cancer drug camizestrant due to concerns about trial design, sending AstraZeneca shares about 2% lower in London. While the panel did not question the drug's safety, it said the SERENA-6 results did not prove that early switching to camizestrant improves long-term survival. The company will continue working with the FDA as it reviews the application, and analysts say the setback may be more sentiment-related than a fundamental issue for the stock.

via CNBC|
#astrazeneca#breast-cancer#business
FDA panel rebuffs AstraZeneca's early ESR1-driven camizestrant approach in breast cancer
health25 days ago

FDA panel rebuffs AstraZeneca's early ESR1-driven camizestrant approach in breast cancer

An FDA advisory panel voted 6-3 against approving AstraZeneca's oral SERD camizestrant for HR-positive, HER2-negative metastatic breast cancer with ESR1 mutations detected before progression, citing insufficient evidence of a meaningful long-term benefit and trial-design concerns (no crossover, OS data immature). Approval now seems unlikely despite a progression-free survival improvement seen in Serena-6.

via Fierce Biotech|
#astrazeneca#breast-cancer#camizestrant
FDA Gears Up Real-Time Trials Fueled by AI to Accelerate Drug Development
health-policy27 days ago

FDA Gears Up Real-Time Trials Fueled by AI to Accelerate Drug Development

The FDA will speed drug development by reviewing real-time trial data from AstraZeneca and Amgen and is seeking public input on a pilot using AI to improve safety monitoring, dosing, and recruitment. The efforts include AZ’s Phase 2 lymphoma trial at MD Anderson and UPenn, and Amgen’s Phase 1b small cell lung cancer study, all supported by Paradigm Health’s real-time data platform.

via statnews.com|
#artificial-intelligence#astrazeneca#clinical-trials
FDA tests real-time clinical-trial reviews to speed approvals
technology27 days ago

FDA tests real-time clinical-trial reviews to speed approvals

The FDA announced a pilot to let reviewers access safety and efficacy signals from ongoing clinical trials in real time via a cloud platform, with AstraZeneca and Amgen participating, aiming to cut development time and speed regulatory decisions without replacing traditional sponsor meetings. A parallel AI pilot to optimize early trials is planned, and public comments are invited, all while safeguarding patient privacy.

via Fierce Biotech|
#ai#amgen#astrazeneca
AZ's tozorakimab delivers COPD benefit across populations in Phase 3
healthcare1 month ago

AZ's tozorakimab delivers COPD benefit across populations in Phase 3

AstraZeneca's anti-IL-33 antibody tozorakimab posted positive Phase 3 results in COPD (Oberon and Titania), reducing the annualized rate of moderate-to-severe exacerbations versus placebo in former smokers and showing benefit across the overall population, with a favorable safety profile. The drug’s supposed differentiation comes from complete inhibition of ST2 and RAGE/EGFR signaling, unlike rivals Roche and Sanofi/Regeneron’s IL-33 blockers that produced mixed results. AZ plans to present full data at an upcoming meeting and is pursuing two additional Phase 3 trials (Prospero, Miranda), while maintaining a target of potentially $3–5 billion in peak sales if approved.

via Fierce Biotech|
#astrazeneca#copd#healthcare
AstraZeneca and Gilead Compete for Leadership in Triple-Negative Breast Cancer Treatments
healthcare7 months ago

AstraZeneca and Gilead Compete for Leadership in Triple-Negative Breast Cancer Treatments

Major pharmaceutical companies Gilead, AstraZeneca, and Roche reported promising new study results for cancer treatments, particularly in breast cancer, leading to stock price increases for Gilead and AstraZeneca, while Roche's shares declined slightly. The studies highlight advancements in drug efficacy and potential growth in the cancer drug market, with implications for future sales and industry competition.

via TipRanks|
#astrazeneca#breast-cancer#cancer
Trump Announces AstraZeneca Drug Price Reductions
business7 months ago

Trump Announces AstraZeneca Drug Price Reductions

President Trump and AstraZeneca announced a deal to lower drug prices by adopting 'most-favored nation' pricing for Medicaid and new drugs, along with discounts on a government website, while AstraZeneca invests in U.S. manufacturing; the agreement includes a tariff exemption but does not directly reduce prices for Medicare or private insurance, with more deals expected from other drug companies.

via Axios|
#astrazeneca#business#drug-prices
healthcare7 months ago

AstraZeneca and Trump Administration Reach Agreement to Lower Drug Prices

AstraZeneca has agreed to lower drug prices for Medicaid by adopting most-favored-nation pricing, matching the lowest prices in developed countries, as part of a deal with the Trump administration aimed at reducing U.S. prescription drug costs. This follows similar agreements with Pfizer and is part of broader efforts to curb drug prices through executive actions and new government initiatives.

via ABC News - Breaking News, Latest News and Videos|
#astrazeneca#drug-prices#healthcare
President Trump Secures New Deal to Lower Drug Prices for Americans
healthcare7 months ago

President Trump Secures New Deal to Lower Drug Prices for Americans

President Trump announced a deal with AstraZeneca to align U.S. drug prices with those of other developed nations, resulting in significant savings for American patients and Medicaid programs, while also investing $50 billion in U.S. pharmaceutical manufacturing and R&D. The agreement includes discounts on key medicines for asthma and COPD, and aims to end the practice of foreign countries subsidizing their healthcare through higher U.S. drug prices.

via The White House (.gov)|
#astrazeneca#drug-pricing#healthcare